Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS

Fig. 2

AMD3100 reduces BSCB permeability and increases tight junction proteins levels. a Evans blue permeability assay. Fifty-day-old SOD1G93A mice were treated with AMD3100 (n = 3) or PBS (n = 3). One hundred ten-day-old mice were IP injected with Evans blue dye (50 ug/g body weight). Three hours post injection mice were sacrificed and perfused, and dye presence in the spinal cord was measured as ratio of tissue weight. b Regional analysis of hemosiderin deposits. c IgG leakage in the lumbar cord anterior horn of SOD1G93A mice treated with AMD3100 (n = 3) or PBS (n = 3) from 50 to 110 days old. Fifteen nonadjacent sections were examined for each treatment group. d Occludin levels of SOD1G93A mice. e Claudin-5 levels of SOD1G93A mice. f ZO-1 levels of SOD1G93A mice. g MCP-1 levels of SOD1G93A mice. For tight junction proteins, SOD1G93A mice were treated with AMD3100 or PBS and sacrificed at 110 days old, and protein levels were measured using western blot. Five mice in each treatment group of SOD1G93A mice were tested. Results are mean ± S.E.M., *p < 0.05, **p < 0.01

Back to article page